Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mitchell Paulin

Physical Medicine & Rehabilitation Paoli, PA Medical Doctor

NPI 1306930243 CMS profile 149714

21 Industrial Blvd Ste 102, Paoli, PA 19301

Open in the dashboard

General payments

$229,296

280 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mitchell Paulin of Paoli, PA is reported in the CMS Open Payments database as having received $229,296 across 280 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,310 29
2024 General $12,733 33
2023 General $59,941 32
2022 General $57,182 60
2021 General $46,927 42
2020 General $16,718 27
2019 General $27,484 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mitchell Paulin
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Mitchell Paulin were reported at $8,310. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Mitchell Paulin Physical Medicine & Rehabilitation median Middle half National median
2019 $27,484 $133 $45–$390 $163
2020 $16,718 $88 $29–$272 $114
2021 $46,927 $116 $33–$360 $132
2022 $57,182 $123 $40–$378 $149
2023 $59,941 $131 $43–$396 $160
2024 $12,733 $141 $45–$409 $164
2025 $8,310 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ipsen Biopharmaceuticals, Inc $99,842 94 payments
  2. Allergan Inc. $58,353 79 payments
  3. AbbVie, Inc. $51,904 68 payments
  4. Merz Pharmaceuticals, LLC $16,291 10 payments
  5. Medtronic, Inc. $1,873 10 payments
  6. Ipsen Pharma SAS $479 2 payments
  7. Revance Therapeutics, Inc. $248 7 payments
  8. Piramal Critical Care $102 1 payment
  9. Merz North America, Inc. $88 1 payment
  10. Medtronic USA, Inc. $71 5 payments
  11. Other $46 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $147,444 42 payments
  2. Consulting Fee $28,946 8 payments
  3. Travel and Lodging $24,410 48 payments
  4. Honoraria $21,170 3 payments
  5. Food and Beverage $7,326 179 payments
Products named General payments · program years 2019–2025
  1. DYSPORT $100,320 96 payments
  2. BOTOX Neuroscience $84,259 67 payments
  3. BOTOX Neuroscience $19,186 17 payments
  4. Xeomin musculoskeletal $16,065 4 payments
  5. BOTOX Botox Therapeutic $3,097 22 payments
  6. BOTOX Facial Aesthetics $1,769 2 payments
  7. SYNCHROMED $1,235 2 payments
  8. SYNCHROMEDII $638 8 payments
  9. BOTOX Hyperhydrosis $315 22 payments
  10. Xeomin musculoskeletal $313 7 payments
  11. Other $835 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

166

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$165,605

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

51.2%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dysport Abobotulinumtoxina Brand 62 $126,105
Botox Onabotulinumtoxina Brand 23 $38,075
Baclofen Generic 35 $1,246
Tizanidine Hcl Generic 31 $145
Diazepam Generic 15 $34

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$962,312

Of which drugs: $704,415

Medicare patients

204

Average age 69

Services billed

125,683

99 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 45%
Depression 28%
Ischemic heart disease 23%
Osteoporosis 22%
Diabetes 15%
Atrial fibrillation 14%
Cancer 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, abobotulinumtoxina, 5 units J0586 Office 116 74,700 $507,370
Injection, onabotulinumtoxina, 1 unit J0585 Office 51 39,500 $194,767

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $10,914
$10,914 23 39,500
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $156
$156 — —
Xeomin
  • Merz Pharmaceuticals, LLC $153
$153 — —
DYSPORT
  • Ipsen Biopharmaceuticals, Inc $102
$102 62 74,700

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

280 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record